Soc. Generale Knock-Out 6MK/ DE000SB0Z0X7 /
2024-03-28 11:54:11 AM | Chg.+0.060 | Bid12:18:20 PM | Ask12:18:20 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
5.570EUR | +1.09% | 5.570 Bid Size: 2,000 |
5.680 Ask Size: 2,000 |
MERCK CO. D... | 71.6339 - | 2078-12-31 | Call |
GlobeNewswire
8:00 AM
Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development
GlobeNewswire
03-27
Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financi...
GlobeNewswire
03-27
Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program ...
GlobeNewswire
03-27
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regula...
GlobeNewswire
03-27
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
GlobeNewswire
03-04
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
2023-12-21
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
2023-12-19
Unnatural Products, Inc. Announces $32 Million in Series A Funding Led by Merck Global Health Innova...
GlobeNewswire
2023-12-14
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
2023-12-12
C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degr...
GlobeNewswire
2023-12-04
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
GlobeNewswire
2023-11-13
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire
2023-10-17
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA